Condition: Lymphoma, B-Cell · Lymphoma, Non-Hodgkin (NHL) · Lymphoma, Large B-Cell, Diffuse (DLBCL) · Sponsor: Umoja Biopharma
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
This description comes directly from the study's public registry record.
Jacob Garcia, MD · 425-873-8331 · jacob.garcia@umoja-biopharma.com
Christine Dehner · christine.dehner@umoja-biopharma.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Not Yet Recruiting |
| The David and Etta Jonas Center for Cellular Therapy | Chicago, Illinois, United States | Recruiting |
| Washington University School of Medicine/Siteman Cancer Center | St Louis, Missouri, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| University of Cincinnatti Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Fred Hutch Cancer Center | Seattle, Washington, United States | Recruiting |
| Royal North Shore Hospital | Saint Leonards, New South Wales, Australia | Recruiting |
| St. Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06528301